GLOW Blend Capsules present the three-component GLOW research formulation, GHK-Cu (Copper Tripeptide-1), BPC-157, and TB-500, in an oral capsule format rather than a lyophilized vial. Each capsule delivers the same three-peptide combination studied for tissue-repair, angiogenic, and extracellular-matrix pathways, packaged for research programs that require a pre-measured solid dosage form. The capsules are offered in 30-count and 60-count presentations.
Component identities and characterization are provided in the profiles below. As with all Helio research materials, GLOW Blend Capsules are supplied strictly for in vitro and preclinical Research Use Only and are not intended for human or veterinary use, diagnosis, or treatment.
Multi-component blend (see profiles)
Research use only — not for human or animal consumption. Per-batch documentation is provided with the material.
The GLOW blend has no single published characterization; the literature exists per component. GHK-Cu is studied for extracellular-matrix and copper-signaling effects, BPC-157 for nitric-oxide and angiogenic pathway modulation in preclinical tissue-repair models, and TB-500 for actin-binding and cell-migration activity. The capsule format packages these three peptides in a pre-measured solid dosage for combined laboratory study.
All reported activity is preclinical and experimental. No human efficacy, dosing, or health conclusions are drawn from the capsule presentation.
GLOW originated as a market-defined research blend combining GHK-Cu, BPC-157, and TB-500; the capsule format adapts that established three-peptide preparation into an oral solid-dosage form for laboratory research use.
Cited literature refers to laboratory and preclinical research. GLOW Blend Capsules is supplied strictly for research use only and is not intended to diagnose, treat, cure, or prevent any disease.
